PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Target Price from Analysts

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) have been given an average recommendation of “Buy” by the five ratings firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $14.25.

Several analysts have recently weighed in on PDSB shares. B. Riley decreased their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, June 12th. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a report on Tuesday. Finally, Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st.

Institutional Investors Weigh In On PDS Biotechnology

A number of large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology in the second quarter worth $146,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in PDS Biotechnology during the 2nd quarter worth about $115,000. Squarepoint Ops LLC bought a new stake in PDS Biotechnology during the 2nd quarter worth about $120,000. Blair William & Co. IL increased its position in PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after acquiring an additional 81,743 shares in the last quarter. Finally, Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology in the second quarter worth about $67,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Trading Down 0.3 %

PDS Biotechnology stock opened at $3.20 on Friday. PDS Biotechnology has a 12 month low of $2.53 and a 12 month high of $6.85. The stock has a market cap of $117.37 million, a price-to-earnings ratio of -2.35 and a beta of 1.88. The business has a 50 day moving average price of $3.34 and a two-hundred day moving average price of $3.47. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same period in the prior year, the firm earned ($0.37) earnings per share. As a group, equities analysts forecast that PDS Biotechnology will post -1.3 EPS for the current year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.